Garadacimab (Andembry): The First-in-Class Factor XIIa Inhibitor for Preventing Hereditary Angioedema Attacks (September 2026 Update)
Table of Contents
- What garadacimab is, in one line
- The problem it targets: the contact system and bradykinin
- What VANGUARD showed
- The FDA approval - and a bleeding-sparing target
- How it compares: garadacimab vs the rest of the HAE toolkit
- The pediatric expansion: a July 2026 milestone
- What we still don't know - and the bottom line
What garadacimab is, in one line
Garadacimab (brand name Andembry; garadacimab-gxii, formerly CSL-312) is a first-in-class, fully human monoclonal antibody that blocks activated Factor XII (FXIIa) - the very first enzyme in the cascade that causes hereditary angioedema swelling - and is given as a once-monthly subcutaneous self-injection to prevent HAE attacks in people aged 12 and older.
The problem it targets: the contact system and bradykinin
Hereditary angioedema (HAE) is a rare genetic disease of sudden, recurrent swelling - of the hands, feet, face, abdomen and, most dangerously, the airway. The root cause in most patients is a shortage or malfunction of C1-esterase inhibitor (C1-INH), the body's natural brake on the plasma contact system. Without that brake, the cascade runs unchecked: Factor XII is activated to FXIIa; FXIIa converts prekallikrein into active plasma kallikrein; kallikrein cleaves high-molecular-weight kininogen; and that releases bradykinin, the peptide that makes blood vessels leaky and produces the painful, sometimes life-threatening edema of an HAE attack. Nearly every modern HAE drug works somewhere along this line. Garadacimab is different in where it acts: it neutralizes FXIIa at the top, shutting the cascade off before kallikrein and bradykinin are ever generated, rather than blocking a single step further downstream.
What VANGUARD showed
The pivotal evidence is VANGUARD (NCT04656418), a global, multicentre, randomized, double-blind, placebo-controlled Phase 3 trial published in The Lancet in 2023. Sixty-four patients aged 12 and older were randomized 3:2 to garadacimab (39 patients) or placebo (25 patients) for a 6-month treatment period, with the monthly number of HAE attacks as the primary endpoint. The result was striking: garadacimab reduced the monthly attack rate by a least-squares mean of 89.2% versus placebo, with a median reduction greater than 99%. Sixty-two percent of garadacimab-treated patients had no attacks at all during the treatment period, whereas none of the placebo patients were attack-free. The drug was generally well tolerated, with adverse-event rates broadly similar to placebo and injection-site reactions among the most common events. A Phase 3 open-label extension has since reported that the attack prevention and quality-of-life gains are durable over long-term dosing.
The FDA approval - and a bleeding-sparing target
Regulators moved quickly. The European Commission authorized garadacimab in February 2025, and on June 16, 2025 the U.S. FDA approved Andembry for the routine prevention of HAE attacks in patients aged 12 and older; it is also approved in Australia and Canada. Dosing is a 400 mg subcutaneous loading dose followed by 200 mg once monthly by subcutaneous self-injection with an autoinjector - an injection that takes about 15 seconds - which CSL positions as the only FXIIa-targeted HAE prophylaxis and one built for once-monthly dosing for all eligible patients from the start. A subtle but important part of the story is safety-by-design: even though Factor XII is a coagulation factor, people born deficient in it do not bleed abnormally, because FXII is largely dispensable for normal hemostasis. That is why blocking FXIIa can calm the contact system without the bleeding risk that inhibiting deeper clotting factors would carry - and no meaningful bleeding signal emerged in the trials.
How it compares: garadacimab vs the rest of the HAE toolkit
Long-term HAE prevention has become a genuinely competitive field, and garadacimab's differentiator is its mechanism and dosing rhythm. Lanadelumab (Takhzyro) is an antibody against plasma kallikrein - one step below FXIIa - dosed every two to four weeks. Berotralstat (Orladeyo) is a once-daily oral plasma kallikrein inhibitor. C1-esterase-inhibitor concentrates such as Haegarda (subcutaneous) and Cinryze (intravenous) replace the missing brake directly and are dosed roughly twice weekly. Donidalorsen (Dawnzera) is a newer antisense drug that lowers production of prekallikrein, the precursor kallikrein comes from. Against that backdrop garadacimab is the only agent that inhibits FXIIa itself, at the top of the cascade, and offers once-monthly subcutaneous dosing from the outset. Separately, on-demand rescue medicines - icatibant, ecallantide and the oral drug sebetralstat - treat attacks once they start; garadacimab does not replace them, because it is a preventive therapy, and patients still need an acute treatment on hand for breakthrough attacks.
The pediatric expansion: a July 2026 milestone
The most recent chapter is about children. On July 27, 2026 CSL reported positive top-line results from a Phase 3b study of garadacimab in children aged 2 to 11 - 22 participants in all, split between ages 2-5 (6 children) and 6-11 (16 children). Most participants remained attack-free across a 12-month treatment period, and the safety and tolerability profile was consistent with earlier studies, with injection-site reactions, abdominal pain and cold-like symptoms among the reported events. The pediatric dosing studied was 100 mg once monthly for ages 6-11 and 100 mg every two months for the youngest group. CSL said it plans to begin filings with health authorities to support an expanded pediatric indication for ages 2-11, with full results to be presented at a scientific congress and submitted for publication. If approved, that would extend a convenient, high-efficacy preventive option to a group with few tailored choices - though, as of this writing, the pediatric indication is not yet approved.
What we still don't know - and the bottom line
Garadacimab has a strong, published Phase 3 dataset, durable open-label extension data, and now positive pediatric top-line results, so the core question - does inhibiting FXIIa prevent HAE attacks? - has a clear answer: yes, and to a large degree. What remains to be filled in over time is the fuller real-world picture: head-to-head comparisons against other modern prophylactics, longer-term outcomes across diverse patients, use in pregnancy and breastfeeding (not established), and the final shape of the pediatric label once regulators review the Phase 3b data. For readers, the takeaways are simple. Garadacimab is a first-in-class, FDA-approved, once-monthly antibody that prevents HAE attacks by switching off the contact system at its first step, with a favorable, bleeding-sparing safety rationale. It is a prescription biologic for a specific rare disease, not a supplement or research chemical, and it is a preventive - not a rescue - therapy. Anyone weighing it should do so with an HAE specialist, alongside the other options in an increasingly rich toolkit.
Ready to track your peptide research?
Open PepTracker ProPepTracker Pro Research Team
The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.
Citations
- [1] Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet (2023) Source
- [2] U.S. FDA Approves CSL's ANDEMBRY (garadacimab-gxii), the Only Prophylactic HAE Treatment Targeting Factor XIIa with Once-Monthly Dosing - CSL Newsroom (June 16, 2025) Source
- [3] FDA Approves Garadacimab-gxii in Hereditary Angioedema - AJMC (2025) Source
- [4] CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY (garadacimab-gxii) in Children with HAE - CSL Newsroom (July 27, 2026) Source
- [5] A Study to Test Garadacimab for the Prevention of Hereditary Angioedema Attacks (VANGUARD) - ClinicalTrials.gov NCT04656418 Source
- [6] Long-term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open-label extension study - The Lancet Haematology (2024) Source
- [7] Garadacimab for the long-term prophylaxis of hereditary angioedema - JDDG: Journal der Deutschen Dermatologischen Gesellschaft (2026) Source
- [8] Garadacimab demonstrates positive results in phase 3b trial for pediatric HAE prophylaxis - Contemporary Pediatrics (2026) Source
Related Articles
Fitusiran (Qfitlia): The First RNAi Therapy for Hemophilia - How Silencing Antithrombin Rebalances Clotting in Hemophilia A and B, With or Without Inhibitors (August 30, 2026)
Most hemophilia drugs replace a missing clotting factor. Fitusiran (Qfitlia) does the reverse: it is an RNAi therapy that silences the antithrombin gene in the liver to rebalance clotting - and in the Phase 3 ATLAS trials it cut bleeds by about 90% in hemophilia A and B, with or without inhibitors. FDA-approved in March 2025, it is the first siRNA therapy for hemophilia, dosed as few as six times a year, and carries a boxed warning for clots.
Donidalorsen (Dawnzera): The First RNA-Targeted Therapy for Hereditary Angioedema - How Silencing Prekallikrein Prevents Bradykinin-Driven Swelling Attacks (August 31, 2026)
Most hereditary angioedema prophylaxis blocks the enzyme kallikrein after it forms. Donidalorsen (Dawnzera) works one step upstream: it is an RNA-targeted antisense drug that silences the liver gene for prekallikrein, so less of the enzyme - and less of the bradykinin that drives swelling - can ever be made. FDA-approved in August 2025 as the first RNA-targeted therapy for HAE, it cut monthly attacks by about 81% in the Phase 3 OASIS-HAE trial, is self-injected as infrequently as every 8 weeks, and carries no boxed warning.
Abelacimab (MAA868): A Once-Monthly Factor XI Antibody Aiming to Prevent Clots Without the Bleeding (September 18, 2026)
Abelacimab (MAA868) is an investigational once-monthly antibody that blocks Factor XI, a clotting protein high in the coagulation cascade. The idea, grounded in human genetics, is to prevent strokes and clots while causing far less bleeding than today's blood thinners. In the Phase 2b AZALEA-TIMI 71 trial it cut bleeding so sharply versus rivaroxaban that the study was stopped early; now Phase 3 trials in anticoagulation-ineligible atrial fibrillation and cancer-associated clots must prove it prevents clots as well as it avoids bleeds.